Business Context and Reporting Period
NewcelX Ltd., a foreign private issuer based in Zurich, Switzerland, filed this Form 6-K for the month of April 2026. The filing announces a definitive private placement financing agreement entered into on April 1, 2026, with certain accredited investors.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Expected to be $1.35 million from the initial purchase of 490,907 common shares or pre-funded warrants at $2.75 per share.
- Warrant Upside: Investors received common warrants to purchase up to 687,270 ordinary shares at an exercise price of $3.025 per share. Full cash exercise would yield an additional approximately $2.1 million.
- Use of Proceeds: Funds will advance the NCEL-101 program for Type 1 Diabetes (in collaboration with Eledon Pharmaceuticals), support other development pipeline activities, and cover working capital and general corporate purposes.
- Existing Liquidity: The company intends to utilize these proceeds alongside a previously announced $25 million equity line.
- Closing Date: Expected on or about April 15, 2026, subject to customary conditions.
Material Changes and Covenants
The filing details a significant capital raise event. Under the Purchase Agreement, NewcelX has agreed to a 60-day lock-up period during which it cannot issue or announce the issuance of common shares or equivalents, nor file new registration statements, subject to customary exceptions. Additionally, the company committed to filing a registration statement for the resale of the securities within 45 calendar days of the agreement date.
Outlook, Risks, and Contingencies
The transaction is subject to customary closing conditions; failure to satisfy these conditions may prevent the offering from closing. The filing includes standard forward-looking statements regarding the timing of the offering and the use of proceeds, noting that actual results may differ due to factors beyond the company's control. The securities are being offered under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, meaning they are unregistered and cannot be resold in the U.S. without an effective registration statement or applicable exemption.
Investor Verification Checklist
- Confirm the actual closing date of the offering (expected April 15, 2026) and whether all closing conditions were satisfied.
- Verify the filing of the resale registration statement within the required 45-day window.
- Monitor the status of the NCEL-101 Type 1 Diabetes program and the collaboration with Eledon Pharmaceuticals.
- Assess the company's cash runway post-closing, considering the $1.35 million proceeds and the $25 million equity line.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific representations and indemnification terms.